Lyell Immunopharma

📍 South San Francisco, United States🗓 Founded 2018👥 265 employees💰 Last funded Mar 2020
Biotechnology Research🌐 lyell.com
Website LinkedIn
Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. At Lyell, our goal is to change that. We are a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for solid tumors based on our innovative technologies. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to defeat solid tumors, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our missions urgency.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Frequently asked questions
Who invested in Lyell Immunopharma?
Lyell Immunopharma has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Lyell Immunopharma last raise funding?
The most recent investment in Lyell Immunopharma recorded on gritt.io was in March 2020.
When was Lyell Immunopharma founded?
Lyell Immunopharma was founded in 2018.
What industry is Lyell Immunopharma in?
Lyell Immunopharma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Lyell Immunopharma based?
Lyell Immunopharma is headquartered in South San Francisco, United States.